The article “Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer” written by A. Matrone, A. Prete, A. Nervo, A. Ragni, L. Agate, E. Molinaro, C. Giani, L. Valerio, E. Minaldi, A. Piovesan and R. Elise was originally published online on the publisher’s internet portal on 17th February 2021 with Open Access under a Creative Commons Attribution (CC BY) license 4.0 With the authors’ decision to cancel Open Access the copyright of the article changed on 28th April 2021 to © Italian Society of Endocrinology (SIE) 2021 with all rights reserved. The original article has been corrected.
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3)
Matrone A.;Prete A.;Agate L.;Molinaro E.;Giani C.;Valerio L.;Minaldi E.;Elisei R.
2021-01-01
Abstract
The article “Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer” written by A. Matrone, A. Prete, A. Nervo, A. Ragni, L. Agate, E. Molinaro, C. Giani, L. Valerio, E. Minaldi, A. Piovesan and R. Elise was originally published online on the publisher’s internet portal on 17th February 2021 with Open Access under a Creative Commons Attribution (CC BY) license 4.0 With the authors’ decision to cancel Open Access the copyright of the article changed on 28th April 2021 to © Italian Society of Endocrinology (SIE) 2021 with all rights reserved. The original article has been corrected.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
